U.S. patent number 3,885,026 [Application Number 05/395,796] was granted by the patent office on 1975-05-20 for preparation of porous tablets.
This patent grant is currently assigned to Boehringer Mannheim GmbH. Invention is credited to Helmut Heinemann, Werner Rothe.
United States Patent |
3,885,026 |
Heinemann , et al. |
May 20, 1975 |
**Please see images for:
( Certificate of Correction ) ** |
Preparation of porous tablets
Abstract
In the production of tablets which are to undergo disintegration
in use wherein the tablet components are mixed and pressed into
predetermined shape, the improvement which comprises incorporating
into the mix at least one inert readily volatilizable solid
adjuvant, pressing the mix into shape, and thereafter volatilizing
the adjuvant, whereby the resulting tablets are porous, strong,
shape retaining and readily disintegratable. Volatilization can be
effected by sublimation or application of vacuum. The adjuvant
preferably comprises urethane, urea, ammonium carbonate, ammonium
bicarbonate, hexamethylene-tetramine, benzoic acid, phthalic
anhydride, naphthalene or camphor present in about 5 to 50 percent,
especially about 10 to 30 percent, by weight of the total tablet
mix.
Inventors: |
Heinemann; Helmut (Heidelberg,
DT), Rothe; Werner (Hockenheim, DT) |
Assignee: |
Boehringer Mannheim GmbH
(Mannheim-Waldhof, DT)
|
Family
ID: |
5856791 |
Appl.
No.: |
05/395,796 |
Filed: |
September 10, 1973 |
Foreign Application Priority Data
|
|
|
|
|
Sep 20, 1972 [DT] |
|
|
2246013 |
|
Current U.S.
Class: |
424/465; 264/101;
264/122; 264/49; 264/109; 106/122; 516/DIG.1 |
Current CPC
Class: |
A61K
9/2095 (20130101); Y10S 516/01 (20130101) |
Current International
Class: |
A61K
9/20 (20060101); A61j 003/10 (); A61k 009/02 ();
B29d 027/00 () |
Field of
Search: |
;264/49,54,117,140,101,109,122 ;23/293R,293A ;241/1,2,18,30 ;424/14
;239/60 ;252/135,531 |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
Other References
The Condensed Chemical Dictionary, Seventh Edition, Completely
revised and enlarged by Arthur and Elizabeth Rose, New York,
Reinhold, C1966, page 995. .
Handbook of Chemistry and Physics, 52nd Edition, Editor: Robert C.
Weast, Cleveland, Ohio, The Chemical Rubber Co., c1971, Page
C-232..
|
Primary Examiner: Anderson; Philip E.
Attorney, Agent or Firm: Burgess & Dinklage &
Sprung
Claims
What is claimed is:
1. In the production of pharmaceutical or reagent tablets which are
to undergo disintegration in use wherein the tablet components are
mixed and pressed into predetermined shape, the improvement which
comprises incorporating into the mix at least one inert solid
adjuvant, sublimable at a temperature up to about 110.degree.C
pressing the mix into tablets, and thereafter subjecting the
tablets to at least one of vacuum and heating to a temperature up
to about 110.degree.C so as to sublime the adjuvant, whereby the
resulting tablets are porous, strong, shape retaining and readily
disintegratable.
2. Process according to claim 1, wherein the adjuvant is sublimed
by application of a vacuum.
3. Process according to claim 1, wherein the adjuvant comprises
about 5 to 50 percent by weight of the total tablet mix.
4. Process according to claim 3, wherein the adjuvant comprises
about 10 to 30 percent by weight of the total tablet mix.
5. Process according to claim 1, wherein the tablet mix
additionally comprises a soluble carrier.
6. Process according to claim 1, wherein the adjuvant is
urethane.
7. Process according to claim 1, wherein the adjuvant is urea.
8. Process according to claim 1, wherein the adjuvant is
hexamethylenetetramine.
9. Process according to claim 1, wherein the adjuvant is benzoic
acid.
10. Process according to claim 1, wherein the adjuvant is phthalic
anhydride.
11. Process according to claim 1, wherein the adjuvant is
naphthalene.
12. Process according to claim 1, wherein the adjuvant is
camphor.
13. The product produced by the process of claim 1.
Description
The present invention is concerned with a new process for the
preparation of porous tablets.
Because of the ease of handling and the simplicity of dosing, not
only pharmaceutical tablets but also reagent tablets are used to an
ever increasing extent for diagnostic and analytical purposes. Most
active materials and reagents cannot be tabletted by themselves
since they form hard tablets which do not readily break down and,
in addition, in many cases, tend to stick in the presses used.
Tablets which break down quickly are only obtained by the addition
of disintegration agents, such as carboxymethyl-cellulose, starch
or the like; filling materials, such as lactose, phosphates or the
like; and lubricants, such as talc, stearic acid, paraffin or the
like. Whereas it is simple to find suitable, physiologically
compatible adjuvants for pharmaceuticals, reagent tablets which,
generally speaking, are to give optically clear solutions, cannot
be produced or can only be produced with difficulty in this manner.
In particular, the lubricants which are generally used and which
are intended to prevent the adherence of the tablet masses in the
presses used are mostly insoluble in water. It has, therefore, been
suggested to press together adhesive reagents with very large
amounts of readily tablettable fillers or to use very high
pressures for the pressing. However, both processes are
unsatisfactory since the tablets formed are either unnecessarily
large or are too hard and difficult to break down.
Another known process gives so-called "molded tablets." In this
case, the tablet components are formed into a paste with water or
an organic solvent, in which at least one of the components
partially dissolves, to give a stiff slurry which is formed in
special machines to give tablets, whereafter the tablets are
carefully dried. Upon evaporation of the solvent, the substances
dissolved therein adhere the undissolved particles, whereby the
tablets receive their strength; at the same time, small hollow
spaces are formed into which solvents can again penetrate when the
tablets are dropped into liquid. Although these tablets are
satisfactory with respect to speed of dissolution they are
frequently too soft and brittle due to the presence of very fine
canals so that difficulties arise in packing and transport.
Furthermore, the use of the process is limited due to the fact that
many reagents, especially enzymes and indicators, are damaged by
solvents, and organic solvent vapors necessitate special safety
precautions during the production of the tablets.
It is, therefore, an object of the present invention to provide a
process which permits the production of readily dissolved, porous
tablets in conventional tablet presses, without having to add
lubricants, explosive agents or solvents.
In accordance with the present invention the conventional process
of mixing tablet components and pressing the mix into predetermined
shape is modified by incorporating into the mix at least one inert
readily volatilizable solid adjuvant, pressing the mix into shape,
and thereafter volatilizing the adjuvant, whereby the resulting
tablets are porous, strong, shape retaining and readily
disintegratable.
Due to the hard pressing in conventional tabletting machines, there
are formed tablets of great mechanical stability and, at the same
time, the addition of sparingly soluble lubricants is unnecessary.
Since the pressed tablets, in contradistinction to "molded
tablets," are form-stable, they no longer shrink upon removal of
the adjuvant. Therefore, when the adjuvant is removed, it leaves
behind comparatively large hollow spaces and canals, through which
solvent can penetrate.
As adjuvants, there can be used, in principle, all readily
sublimable materials or materials which can readily be converted
into gaseous decomposition products and which are readily
tablettable and do not react with the other components of the
tablets. By way of example, there may be mentioned urethane, urea,
ammonium carbonate and bicarbonate, hexamethylene-tetramine,
benzoic acid, phthalic anhydride, naphthalene and camphor, urethane
being especially preferred.
The tablet masses for water-soluble reagent tablets and
pharmaceutical tablets can, in addition to one or more active
materials, contain conventional soluble carrier materials, for
example sodium chloride, potassium chloride, borax, phosphates,
oligosaccharides, polyethylene glycols, tensides and other
appropriate inorganic and organic materials. The volatile solid
adjuvants can account for about 5 - 50 percent and preferably about
10-30 percent of the total tablet mass, it being understood that in
the case of a high proportion of adjuvant there are formed
comparatively large hollow spaces and thus tablets which break down
more quickly but are also more brittle than in the case of using a
small proportion of adjuvant. Although the adjuvants can be
completely removed, the production time for the new tablets
according to the present invention is shortened when the adjuvants
are allowed to remain behind in the tablets in trace amounts, for
example of less than about 1% by weight.
Where the tablet components are of sufficient thermal stability,
the adjuvants can be removed by simple heating of the tablets above
the sublimation or decomposition point. In the case of sensitive
tablet components, for example of enzymes, it is advantageous to
work in a vacuum, the conventional freeze drying plants with
condensation separator having proved to be especially advantageous
for this purpose.
The following Examples are given for the purpose of illustrating
the present invention:
EXAMPLE 1
Tablet A: 1.850 kg of potassium chloride are sieved and pressed to
form tablets of 8 mm diameter containing 185 mg of potassium
chloride.
Tablet B1: 1.850 kg of potassium chloride are mixed with 350 g of
urethane (ethyl-urethane), sieved and pressed to form tablets of 8
mm diameter containing 185 mg of potassium chloride and 35 mg of
urethane.
The urethane is subsequently sublimed from these tablets over 5
hours in a freeze drying plant at 20.degree.C and at a pressure of
10.sup..sub.-1 to 10.sup..sub.-3 mm Hg.
Tablet B2: 1.850 kg of potassium chloride are mixed with 350 g of
ammonium bicarbonate, sieved and pressed to form tablets of 8 mm
diameter containing 185 mg of potassium chloride and 35 mg of
ammonium bicarbonate.
The ammonium bicarbonate is driven off from these tablets over 8
hours in a drying cabinet at 90.degree.C.
Tablet B3: 1.850 kg of potassium chloride are mixed with 350 g of
urea, sieved and pressed to form tablets of 8 mm diameter
containing 185 mg of potassium chloride and 35 mg of urea.
The urea is sublimed from these tablets over 16 hours in a vacuum
cabinet at 110.degree.C and 15 mm Hg.
Tablet B4: 1.850 kg of potassium chloride are mixed with 350 g of
urotropin, sieved and pressed to form tablets of 8 mm diameter
containing 185 mg of potassium chloride and 35 mg of urotropin.
The urotropin is removed from these tablets over 16 hours in a
vacuum cabinet at 90.degree.C and 15 mm Hg.
The results of tests carried out on these tablets are set out in
the following Table 1:
TABLE 1 ______________________________________ Tablet Height,
Hardness, Dissolving Breakability, mm kg Time, sec. sec.
______________________________________ A 2.3 9.5 240 150 B1-B4 2.9
3.5 105 30 ______________________________________
Determination of the tablet hardness: with an Erweka hardness
tester.
Determination of the dissolving time: 200 ml of water at ambient
temperature are stirred at a rate of 150 r.p.m. in a 250 ml glass
beaker with a curved glass rod. The time needed for complete
dissolution is determined.
Determination of breakability: a tablet placed on its edge in a
Petri dish is compressed with a rod with an applied weight of 500
g. The Petri dish is filled with water at ambient temperature and
the time determined for the tablet to break.
EXAMPLE 2
Tablet C: 1.5 kg of dextrose are granulated with 300 ml of 40
percent aqueous alcohol, dried and sieved. The granulate is dry
mixed with 50 g of polyethylene glycol (M.W. 5000 - 6000) and
pressed to form tablets of 8 mm diameter containing 150 mg of
dextrose.
Tablet D1: 1.550 kg of dextrose-polyethylene glycol granulate are
dry mixed with 300 g of urethane. The tablet mass is pressed to
form tablets of 8 mm diameter containing 150 mg of dextrose and 30
mg of urethane.
The urethane is sublimed from these tablets over 8 hours in a
drying cabinet at 40.degree.C.
Tablet D2: 1.550 kg of dextrose-polyethylene glycol granulate are
dry mixed with 300 g of ammonium carbonate. The tablet mass is
pressed to form tablets of 8 mm diameter containing 150 mg of
dextrose and 30 mg of ammonium carbonate.
The ammonium carbonate is removed from these tablets over 8 hours
in a drying cabinet at 75.degree.C.
Tablet D3: 1.550 kg of dextrose-polyethylene glycol granulate are
dry mixed with 300 g of benzoic acid. The tablet mass is pressed to
form tablets of 8 mm diameter containing 150 mg of dextrose and 30
mg of benzoic acid.
The benzoic acid is sublimed from these tablets over 16 hours in a
vacuum cabinet at 90.degree.C and 15 mm Hg.
Tablet D4: 1.550 kg of dextrose-polyethylene glycol granulate are
dry mixed with 300 g of camphor. The tablet mass is pressed to form
tablets of 8 mm diameter containing 150 mg of dextrose and 30 mg of
camphor.
The camphor is removed from these tablets over 8 hours in a freeze
drying device at 40.degree.C and 10.sup..sub.-1 to 10.sup..sub.-3
mm Hg.
The results of tests carried out on these tablets, in the manner
described in Example 1, are set out in the following Table 2:
TABLE 2 ______________________________________ Tablet Height,
Hardness, Dissolving Breakability, mm kg Time, sec. sec.
______________________________________ C 2.7 4.5 360 210 D1-D4 3.3
1.0 270 <10 ______________________________________
EXAMPLE 3
Tablet E: 15 g of polyethylene glycol (M.W. 5000 - 6000) are
dissolved in 80 ml of 40 percent aqueous ethanol. With this
solution, there are mixed 388 g of glucose, which is then dried and
sieved. The granulate obtained is dry mixed with 12.5 g of
nicotinamide-adenine-dinucleotide (NAD), 3.75 g of
2,5-diphenyl-3-(4,5-dimethyl-thiazolyl-2)-tetrazolium bromide (MTT)
and 0.75 g of N-methylphenazine-methylsulfate (PMS). The mixture is
pressed to form tablets of 12 mm diameter, each tablet containing
12.5 mg of NAD, 3.75 mg of MTT and 0.75 mg of PMS.
Tablet F: 15 g of polyethylene glycol (M.W. 5000 - 6000) are
dissolved in 80 ml of 40 percent aqueous alcohol. With this
solution, there are mixed 388 g of glucose, which is then dried and
sieved. The granulate obtained is dry mixed with 12.5 g of NAD,
3.75 g of MTT, 0.75 g of PMS and 80 g of urethane. The mixture is
pressed to form reagent tablets of 12 mm diameter which contain,
per tablet, 12.5 mg of NAD, 3.75 mg of MTT and 0.75 mg of PMS. The
urethane is sublimed from these tablets over 8 hours in a freeze
drying plant at 0.degree.C and 10.sup..sub.-1 to 10.sub.-3 mm
Hg.
The results of tests carried out on these tablets, in the manner
described in Example 1, are set out in the following Table 3:
TABLE 3 ______________________________________ Tablet Height,
Hardness, Dissolving Breakability, mm kg Time, sec. sec.
______________________________________ E 3.5 12 660 540 F 4.2 3 480
<15 ______________________________________
EXAMPLE 4
Tablet G: 500 g of sodium chloride are ground, mixed with 116 g of
sodium p-nitrophenyl phosphate, precompressed and sieved. There are
then pressed tablets of 5 mm diameter each containing 11.6 mg of
sodium p-nitrophenyl phosphate.
Tablet H: 500 g of sodium chloride are ground, mixed with 116 g of
sodium p-nitrophenyl phosphate and 134 g of urethane, precompressed
and sieved. There are then pressed tablets of 5 mm diameter
containing 11.6 mg of sodium p-nitrophenyl phosphate. These tablets
are heated for 10 hours in a drying cabinet at 30.degree.C to
sublime the urethane.
The results of tests carried out on these tablets, in the manner
described in Example 1, are set out in the following Table 4:
TABLE 4 ______________________________________ Tablet Height,
Hardness, Dissolving Breakability mm kg Time, sec. sec.
______________________________________ G 1.9 3 300 60 H 2.4 1 120
<10 ______________________________________
The various components of the tablet mix including active
materials, adjuvant, carrier, etc., may range in size from about
0,01 to 1,0 and preferably about 0.05 to 0,5 mm. Desirably the
average size of the adjuvant particles ranges from about 5 to 50
percent and preferably about 10 to 30 percent of that of the
balance of the particles making up the tablet mix.
It will be appreciated that the instant specification and examples
are set forth by way of illustration and not limitation, and that
various modifications and changes may be made without departing
from the spirit and scope of the present invention.
* * * * *